A meeting held in Boston by Biogen Management in late February has had 108 presumptive positive or confirmed cases of the novel coronavirus, and has led to a fully fledged criminal investigation.
The world’s first licensed, downloadable artificial pancreas app for people with type I diabetes has been launched in the UK, in a bid to move closer to making full artificial pancreas technology available for everyone with the disorder.
Merck KGaA and Pfizer have decided to stop their Phase III JAVELIN study testing Bavencio (avelumab) as a potential treatment for certain patients with advanced head and neck cancer.
A clinical preliminary bolstered by the National Institute for Health Research (NIHR) has discovered that another treatment for pregnant ladies at high danger of preterm birth can avoid both very preterm birth and passing of infants.
Johnson and Johnson has declared the accommodation of Marketing Authorisation Applications (MAAs) to the European Medicines Agency (EMA) for its investigational Ebola immunization routine.
Vertex has declared victories from two Phase III investigations of Trikafta for the treatment of certain cystic fibrosis in individuals ages 12 years and more seasoned.
Nova Laboratories has declared subtleties of its “progressive” new fluid arrangement of hydroxycarbamide for sickle cell ailment.
The last period of the NHS’ Electronic Prescription Service (EPS) turn out is set to go live on November eighteenth, starting with GP works on utilizing the TPP SystmOne framework.
Another universal coalition made up of Cancer Research UK and accomplices has reported designs to create “radical new methodologies” and innovations to identify malignant growth at its soonest organize.
The most recent yearly evaluation of doctors in the UK has been discharged, uncovering “proceeding with weights on the medicinal workforce and NHS frameworks.”
Collaboration between University of Bristol and Malvern Panalytical to boost data science and digital technologies expertise.
Malvern UK, 24th September, 2019: A formal partnership has been agreed between the University of Bristol and analytical instrumentation provider Malvern Panalytical.
Malvern Panalytical, a global leader in high-performance analytical instrumentation and material analysis solutions, announces a new Reliability Commitment for its Claisse® instruments to provide customer satisfaction through absolute peace of mind.
Janssen has declared information from two significant Phase III clinical examinations demonstrating that the nasal splash Spravato (esketamine) caused a decrease in burdensome indications at 24 hours after the primary portion, as estimated by the Montgomery-Åsberg Depression Rating Scale (MADRS).
The NHS has reported designs to survey making statins accessible direct from drug specialists, as a feature of Long Term Plan. The association has declared that high portion statins could be made accessible legitimately from high road drug stores as a major aspect of the arrangement, so as to cut coronary illness and stroke.
The new video GP administration comes as a feature of an agreement, which expresses that all patients ought to approach on the web and video counsels by 2021 as a major aspect of the NHS Long Term Plan.
The US Food and Drug Administration (FDA) has conceded Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE), AstraZeneca has declared.
Ionis pharmaceuticals has reported that GlaxoSmithKline (GSK) has practiced its alternative to permit Ionis’ antisense medications for individuals with interminable hepatitis B infection (CHB) disease following positive Phase II results.
AZ To Be Fast Tracked By The FDA
AstraZeneca has reported that the US Food and Drug Administration (FDA) has conceded Fast Track assignment for the improvement of Forxiga (dapagliflozin).
The National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) have issued draft antimicrobial endorsing direction on impetigo.
Novo Nordisk has reported that the European Commission has allowed an expansion of the sign for its quick acting insulin aspart, Fiasp.
The Scottish Obesity Alliance has approached first serve, Nicola Sturgeon, to acquaint guideline with limit value advancements and ideally help ‘control the stoutness emergency’.
New figures from NHS Digital have uncovered that students who have as of late smoked, alcoholic liquor and ingested medications are bound to be ‘miserable’.
The new PM, Boris Johnson, has requested earnest activity to improve immunization take-up after in excess of 230 instances of measles were accounted for in the UK during first quarter of 2019.
Mallinckrodt has reported positive top-line results from its vital Phase III CONFIRM clinical investigation of terlipressin.
Another support of convey dire meds and therapeutic items into the UK has been set up as a major aspect of Brexit arrangements, the Department of Health and Social Care has reported.
Enormous buzzwords can cause huge disarray. Take Artificial-inteligence: In pharma, the innovation has been touted as everything from the following huge medication tracker to an altered specialized instrument.
A new investigation distributed in the British Journal of General Practice has announced that youth anti-microbial presentation has significant clinically applicable ramifications, including disturbance to the microbiome, anti-infection opposition, and clinical remaining task at hand showing as treatment ‘failure’.
Another report from Asthma UK has discovered that passings from asthma assaults are the most noteworthy they have been in the most recent decade, and have expanded by over 33% in the course of the most recent ten years.
The news implies that the syringe is currently accessible for use on the NHS for the treatment of grown-up patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), manifestations related with neuroendocrine (especially carcinoid) tumors (NETs), and acromegaly.
Cancer Research UK and Hummingbird Bioscience have collaborated to build up the anti-HER3 immune antibody medicate, HMBD-001, for the treatment of individuals with HER3 driven cancer.
The European Commission has affirmed an update to the marketing authorisation for AstraZeneca’s Forxiga (dapagliflozin) to incorporate positive cardiovascular (CV) outcomes…
A new study from Aarhus University and Aarhus University Hospital has found that elderly people who have been in intensive care units have less risk of dying and of suffering a blood clot or bleeding in the brain if they have been vaccinated for the flu.
E-theraputics have signed an extension to their existing research collaboration with Novo Nordisk in the type II diabetes space…
The US Food and Drug Administration (FDA) has approved Eli Lilly’s non-steroidal androgen receptor inhibitor (ARi), Nubeqa (darolutamide), for men that have non-metastatic castration-resistant prostate cancer.
ViiV submits regulatory application to EMA for investigational HIV combo
ViiV Healthcare have submitted a regulatory application to the European Medicines Agency (EMA) for investigational drug cabotegravir to be used with Janssen’s Edurant (rilpivirine) as the first monthly, treatment for HIV using injections.
The new Prime Minister of the UK, Boris Johnson, has come out and said that patients should get quicker access to GP appointments, and hospitals will receive “upgrades” as part of new plans.
Gilead has announced plans to licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.
Medical device company Flow has announced that it has raised $1.5m in an investment round led by Khosla Venturesto tackle the world’s most urgent mental health challenges, such as depression.
Boston-based Vertex Pharmaceuticals has announced it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its triple combination therapy for cystic fibrosis (CF), VX-445 (elexacaftor), tezacaftor and ivacaftor.
Boehringer Ingelheim has entered a collaboration and licence agreement to develop South Korea-based Bridge Biotherapeutics’ drug candidate for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).
New York-based RNA-focused drug discovery company Gotham Therapeutics and German contract research organization (CRO) Mercachem have announced they have created a high-quality compound library focused on epitranscriptomic drug discovery.
Boehringer Ingelheim has expanded its cancer immunology portfolio with the acquisition of Swiss biotechnology firm AMAL Therapeutics for up to €325m ($366m).
Dutch biopharmaceutical company AM-Pharma has raised €116m from a European syndicate of new and existing investors. The funding will be used to support the initiation of a Phase III trial of its recombinant human alkaline phosphatase (recAP) therapeutic for patients with sepsis-associated acute kidney injury (SA-AKI).
Amgen and Novartis have announced the discontinuation of their clinical development programme for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer’s disease, which the Arizona-based Banner Alzheimer’s Institute was also supporting.
German pharma company vasopharm has announced it has closed a €9.5m financing round, which was co-led by HeidelbergCapital Private Equity and EF Investments.
Lyndra Therapeutics and Gilead Sciences have entered a partnership collaboration to develop and market ultra-long-acting oral HIV therapies. Gilead will pick up exclusive rights to Lyndra’s long-acting drug platform.
Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will lead a consortium for the development of small-molecule negative allosteric modulators
NICE recommends Pfizer’s dacomitinib for NSCLC patients
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Pfizer’s dacomitinib (Vizimpro) as a first-line treatment for non-small-cell lung cancer (NSCLC) patients on the National Health Service (NHS).
A small chemical change — shifting the position of two hydrogen atoms — makes the difference between mice that are healthy and mice with insulin resistance and fatty liver, major risk factors for diabetes and heart disease. Making the change prevented the onset of these symptoms in mice fed a high-fat diet and reversed prediabetes in obese mice.
MORGANTOWN, W.Va.–Medications attach to the proteins in our bodies the way spacecrafts dock into the International Space Station.
Pfizer has announced it has completed its acquisition of US-based Therachon, a clinical stage biotechnology company focusing on rare diseases; the acquisition was first initiated in early May 2019.
The Food and Drug Administration (FDA) has approved Zirabev (bevacizumab-bvzr; Pfizer), a biosimilar to Avastin (bevacizumab; Genentech).
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced the licensing of two Melatonin products indicated forshort-term jet-lag treatment in adults.
The European Investment Bank (EIB) has granted a €120m loan to Spanish pharmaceutical company Almirall to support its research…
Study shows vaccine has greatly reduced infections among girls and young women
The Patient Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) has changed its stance regarding an interference between ten patent applications…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6 through 11 years